In yesterday’s Wall Street session, Revance Therapeutics Inc (NASDAQ:RVNC) shares traded at $3.08, up 0.33% from the previous session.
RVNC stock price is now -28.10% away from the 50-day moving average and -28.94% away from the 200-day moving average. The market capitalization of the company currently stands at $319.44M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $16 to $9, Mizuho Downgraded its rating from Buy to Neutral for Revance Therapeutics Inc (NASDAQ: RVNC). On January 09, 2024, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $30 to quote $8, while ‘Exane BNP Paribas’ rates the stock as ‘Neutral’
In other news, Hollander David, CMO & Global Therapeutics Lead sold 3,908 shares of the company’s stock on Nov 18 ’24. The stock was sold for $16,296 at an average price of $4.17. Upon completion of the transaction, the CMO & Global Therapeutics Lead now directly owns 104,945 shares in the company, valued at $0.32 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 16 ’24, Chief Commercial Officer Jordan Erica sold 2,392 shares of the business’s stock. A total of $9,096 was realized by selling the stock at an average price of $3.80. This leaves the insider owning 114,864 shares of the company worth $0.35 million. A total of 8.71% of the company’s stock is owned by insiders.
During the past 12 months, Revance Therapeutics Inc has had a low of $2.30 and a high of $9.74. The fifty day moving average price for RVNC is $4.3251 and a two-hundred day moving average price translates $4.3506 for the stock.
The latest earnings results from Revance Therapeutics Inc (NASDAQ: RVNC) was released for 2024-09-30. The net profit margin was -74.67% and return on equity was -2096.78% for RVNC. The company reported revenue of $59.88 million for the quarter, compared to $54.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.66 percent.
